Wed, Jul 23, 2014, 3:05 PM EDT - U.S. Markets close in 55 mins.

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • swordfish47 swordfish47 Jan 26, 2013 11:10 AM Flag

    dog trial

    Is there an exact date that dog trial started, hence where the 9 months will be.... Is in Feb or March?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 9 months + data +gleaning = second quarter.

    • The company has consistantly reported the dog trial results are due to be released in mid second quarter. May
      CF results due mid year June

      Sentiment: Hold

    • Guidance from SEC filings -

      "We also initiated a nine-month dog inhalation toxicity study in April 2012."

      "We currently expect to have top line data available from this study in the second quarter of 2013."

      If the dog study was initiated on April 1 last year it would have been completed last month.

    • I don't think that a start date was ever announced. It was just stated that the dog studies would begin in the second quarter of 2012. If we assume that they started late June, then that would take it out to the end of March. 60 to 90 days after that for results?

      • 1 Reply to kinionq
      • Insmed had a quarterly report on May 8th which mentions that the dog trial commenced already. So, April would have been the time. I see Fud posted something that April was the time......so , April 1-30 is the best I see at present without taking the time to research further.

        MONMOUTH JUNCTION, N.J., May 8, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012.

        Key Recent Highlights:

        U.S. Food and Drug Administration (FDA) lifted clinical hold on ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infections;
        Initiated dosing in CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACE for CF patients;
        U.S. phase 2 clinical trial for ARIKACE in the non-tuberculous mycobacterial (NTM) lung disease indication on track to begin in mid-2012;
        Commenced dosing for nine-month inhalation dog toxicity study.
        "We are pleased FDA has lifted the clinical hold on ARIKACE in CF patients, and are excited about the important recent progress we have made with our ARIKACE development program," said Timothy Whitten, President and CEO of Insmed. "Many of the trial sites for CLEAR-108 are up and running, including those in key European countries and we are also proceeding with this study in Canada. We anticipate top-line efficacy and safety data in mid-2013. In addition, we are working towards initiating our phase 2 U.S. clinical trial for ARIKACE in NTM patients in mid-2012."

        "We are at a point of significant focused activity with our ARIKACE development program, and continue to believe that ARIKACE provides a late-stage, potentially highly differentiated opportunity, with significant global commercial potential in both CF and NTM," continued Mr. Whitten. "Importantly, we believe our current cash position is sufficient to generate top-line data from CLEAR-108 and the randomized portion of the U.S. phase 2 clinical trial for ARIKACE in NTM."

 
INSM
18.24+0.54(+3.05%)3:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.